Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
4.780
-0.070 (-1.44%)
At close: May 18, 2026, 4:00 PM EDT
4.710
-0.070 (-1.46%)
After-hours: May 18, 2026, 4:41 PM EDT
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
41.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nutriband | 2.04M |
| RenovoRx | 1.12M |
| Hyperion DeFi | 813.46K |
| Mereo BioPharma Group | 500.00K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
ATOS News
- 4 days ago - Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - PRNewsWire
- 10 days ago - Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year - TheFly
- 10 days ago - Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 11 days ago - Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial - TheFly
- 12 days ago - Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women - PRNewsWire
- 14 days ago - Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS - TheFly
- 14 days ago - Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - PRNewsWire
- 7 weeks ago - Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright - TheFly